⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 25, 2024British Journal of Clinical PharmacologyOpen Access

Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease

Muhammad Waqas Sadiq Hongtao Yu Magnus Åstrand Ian C. Scott Adam Williams Lisa Hewitt N. E. White Helen Killick Monica L. Gavala E. Suzanne Cohen Fred Reid Chris Kell Hitesh Pandya Eulalia Jiménez

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study describes the pharmacokinetic (PK)/target engagement (TE) relationship of tozorakimab, an anti-interleukin (IL)-33 antibody, by building a mechanistic population PK/TE model using phase 1 biomarker data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sadiq et al. (2024) studied this question.

synapsesocial.com/papers/68e5b019b6db643587549475 https://doi.org/10.1111/bcp.16195

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants2024 · 2 citations
2B15-06 Tozorakimab, an Anti-IL-33 Antibody, Modulates Pathways Associated With Airway Inflammation and Tissue Dysfunction in COPD Patients: Mechanistic Evidence From FRONTIER-4Late-Phase Clinical Trial · 2026
3B22-14 Tozorakimab, an Anti-interleukin-33 Antibody, Inhibits T2 and T1 Inflammatory Pathways in the Airway of Patients With Uncontrolled, Early-Onset, Asthma in FRONTIER-3Early-Phase Clinical Trial · 2026
4FRONTIER-3: a randomised phase 2a study to investigate tozorakimab (an anti-IL-33 mAb) in early onset asthma2025 · 7 citations
5#2267 IL-33 Inhibition with tozorakimab for diabetic kidney disease: a randomized, placebo-controlled phase 2b study2024 · 1 citations

More related papers

Inhibition of Interleukin-33 in Diabetic Kidney Disease2025
D96-08 Tozorakimab Improves Quantitative Mucus Plugging Metrics in Patients With Moderate-to-Severe COPD2026
Population PK/PD Modeling and Simulation to Predict the Comparative Long-Term Efficacy of Olokizumab in Rheumatoid Arthritis Patients2026

More from British Journal of Clinical Pharmacology

Desethylhydroxychloroquine and CYP2D6 polymorphisms are associated with low disease activity in patients with systemic lupus erythematosusFri,
Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysisSat,